PURPOSE: To evaluate the safety and efficacy of the ALLEGRETTO WAVE excimer laser system (WaveLight Laser Technologie AG, Erlangen, Germany) in LASIK for hyperopia and hyperopic astigmatism. METHODS: One hundred twenty consecutive LASIK cases for hyperopia with or without astigmatism treated with the ALLEGRETTO WAVE excimer laser were prospectively evaluated up to 12 months postoperatively. Patients were allocated into three groups according to their refractive sphere and cylinder: a low hyperopia group, with up to +3.00 diopters (D) sphere and astigmatism < or = +1.00 D (n = 52); a moderate hyperopia group with +3.25 to +5.00 D sphere and astigmatism of < or = +1.00 D (n = 45); and a high hyperopia/toric group with sphere > or = +5.25 D or cylinder > or = +1.25.D (n = 23). Flaps were created with the Moria M2 microkeratome (Moria, Antony, France). Parameters evaluated were pre- and postoperative refractive error, uncorrected visual acuity, best spectacle-corrected visual acuity (BSCVA), higher order aberration change, and contrast sensitivity. RESULTS: One hundred twelve eyes (93%) were available for follow-up at 12 months. Of the eyes in the low hyperopia group, 92% were within +/- 0.50 D of the refractive goal. For the moderate sphere group and the high hyperopia/toric group, 79% and 71% of eyes, respectively, were within +/- 0.50 D of the refractive goal. No eye lost > or = 2 lines of BSCVA. An increase in higher order aberrations was noted in the high hyperopia/toric group from 0.47 microm (+/- 0.096) to 0.94 microm (+/- 0.167) (P < .001). No significant changes in higher order aberrations were noted in the low and moderate hyperopia groups. CONCLUSIONS: Hyperopic LASIK using the WaveLight ALLEGRETTO WAVE excimer laser appears to be safe and effective in the correction of low, moderate, and high hyperopia and hyperopic astigmatism.
PURPOSE: To evaluate the safety and efficacy of the ALLEGRETTO WAVE excimer laser system (WaveLight Laser Technologie AG, Erlangen, Germany) in LASIK for hyperopia and hyperopic astigmatism. METHODS: One hundred twenty consecutive LASIK cases for hyperopia with or without astigmatism treated with the ALLEGRETTO WAVE excimer laser were prospectively evaluated up to 12 months postoperatively. Patients were allocated into three groups according to their refractive sphere and cylinder: a low hyperopia group, with up to +3.00 diopters (D) sphere and astigmatism < or = +1.00 D (n = 52); a moderate hyperopia group with +3.25 to +5.00 D sphere and astigmatism of < or = +1.00 D (n = 45); and a high hyperopia/toric group with sphere > or = +5.25 D or cylinder > or = +1.25.D (n = 23). Flaps were created with the Moria M2 microkeratome (Moria, Antony, France). Parameters evaluated were pre- and postoperative refractive error, uncorrected visual acuity, best spectacle-corrected visual acuity (BSCVA), higher order aberration change, and contrast sensitivity. RESULTS: One hundred twelve eyes (93%) were available for follow-up at 12 months. Of the eyes in the low hyperopia group, 92% were within +/- 0.50 D of the refractive goal. For the moderate sphere group and the high hyperopia/toric group, 79% and 71% of eyes, respectively, were within +/- 0.50 D of the refractive goal. No eye lost > or = 2 lines of BSCVA. An increase in higher order aberrations was noted in the high hyperopia/toric group from 0.47 microm (+/- 0.096) to 0.94 microm (+/- 0.167) (P < .001). No significant changes in higher order aberrations were noted in the low and moderate hyperopia groups. CONCLUSIONS: Hyperopic LASIK using the WaveLight ALLEGRETTO WAVE excimer laser appears to be safe and effective in the correction of low, moderate, and high hyperopia and hyperopic astigmatism.